In conclusion, receptor conversion in distant non-bone breast cancer metastases indeed occurs, is relatively uncommon for ERα and HER2, more frequent for PR, and seems to be more frequent in liver and brain metastases. Here, ERBB2 is linked to breast carcinoma.